ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

被引：137

作者：

Kwekkeboom, Dik J. ^{[1
]}

Krenning, Eric P.

Lebtahi, Rachida ^{[2
]}

Komminoth, Paul ^{[3
]}

Kos-Kudla, Beata ^{[4
]}

de Herder, Wouter W. ^{[5
]}

Ploeckinger, Ursula ^{[6
]}

机构：

[1] Erasmus Univ, Dept Nucl Med, Med Ctr, Erasmus MC, NL-3015 Rotterdam, Netherlands

[2] Hop Xavier Bichat, Dept Nucl Med, Paris, France

[3] Stadtspital Triemli, Inst Pathol, Zurich, Switzerland

[4] Slaska Akad Med Klin Endokrynol, Zabrze, Poland

[5] Erasmus MC, Endocrinol Sect, Dept Internal Med, Rotterdam, Netherlands

[6] Charite, Campus Virchow Klinikum, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany

来源：

NEUROENDOCRINOLOGY | 2009年 / 90卷 / 02期

关键词：

Radiolabeled somatostatin analogues; GEPNET; Neuroendocrine tumors; Carcinoids; TYR(3) OCTREOTATE; PHASE-I; Y-90-DOTATOC; LU-177-DOTA(0); MALIGNANCIES; EXPERIENCE; SURVIVAL; EFFICACY; PRRT;

D O I：

10.1159/000225951

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The purpose of this guideline is to assist physicians caring for patients with neuroendocrine tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT), and in defining the minimum requirements for PRRT. This guideline also makes recommendations on what minimal patient, tumor, and treatment outcome characteristics should be reported for PRRT in order to make comparisons between studies possible. It is not this guideline's aim to give specific recommendations on the use of specific radiolabeled somatostatin analogs for PRRT because different analogs are being used, and their availability depends on national law and local permissions. Copyright (C) 2009 S. Karger AG, Basel

引用

页码：220 / 226

页数：7

共 22 条

[1] Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies [J].

Anthony, LB ;

Woltering, EA ;

Espenan, GD ;

Cronin, MD ;

Maloney, TJ ;

McCarthy, KE .

SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (02) :123-132

[2]

Baum RP, 2004, EUR J NUCL MED MOL I, V31, pS238

[3]

Baum RP., 2004, ONKOLOGE, V10, P1098, DOI DOI 10.1007/S00761-004-0771-7

[4] Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:: a phase I study [J].

Bodei, L ;

Cremonesi, M ;

Zoboli, S ;

Grana, C ;

Bartolomei, M ;

Rocca, P ;

Caracciolo, M ;

Mäcke, HR ;

Chinol, M ;

Paganelli, G .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (02) :207-216

[5]

Buscombe JR, 2003, J NUCL MED, V44, P1

[6]

Bushnell D, 2003, J NUCL MED, V44, P1556

[7] Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide:: The experience of the European Institute of Oncology Group [J].

Chinol, M ;

Bodei, L ;

Cremonesi, M ;

Paganelli, G .

SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (02) :141-147

[8] Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate [J].

de Keizer, Bart ;

van Aken, Maarten O. ;

Feelders, Richard A. ;

de Herder, Wouter W. ;

Kam, Boen L. R. ;

van Essen, Martijn ;

Krenning, Eric P. ;

Kwekkeboom, Dik J. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (04) :749-755

[9] Comparison of [177Lu-DOTA0, Tyr3] octreotate and [177Lu- DOTA0, Tyr3] octreotide:: which peptide is preferable for PRRT? [J].

Esser, J. P. ;

Krenning, E. P. ;

Teunissen, J. J. M. ;

Kooij, P. P. M. ;

van Gameren, A. L. H. ;

Bakker, W. H. ;

Kwekkeboom, D. J. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (11) :1346-1351

[10] Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival [J].

Kwekkeboom, Dik J. ;

de Herder, Wouter W. ;

Kam, Boen L. ;

van Eijck, Casper H. ;

van Essen, Martijn ;

Kooij, Peter P. ;

Feelders, Richard A. ;

van Aken, Maarten O. ;

Krenning, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2124-2130

← 1 2 3 →